139 related articles for article (PubMed ID: 27690233)
1. Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.
Attia SM; Ahmad SF; Ansaria MA; Nadeem A; Al-Shabanah OA; Al-Harbi MM; Bakheet SA
PLoS One; 2016; 11(9):e0163703. PubMed ID: 27690233
[TBL] [Abstract][Full Text] [Related]
2. Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells.
Attia SM; Ahmad SF; Saquib Q; Harisa GI; Al-Khedhairy AA; Bakheet SA
Mutagenesis; 2016 Mar; 31(2):137-45. PubMed ID: 26399706
[TBL] [Abstract][Full Text] [Related]
3. Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells.
Bakheet SA; Attia SM; Al-Rasheed NM; Al-Harbi MM; Ashour AE; Korashy HM; Abd-Allah AR; Saquib Q; Al-Khedhairy AA; Musarrat J
Mutagenesis; 2011 Jul; 26(4):533-43. PubMed ID: 21430063
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice.
Attia SM; Ahmad SF; Bakheet SA
Cancer Chemother Pharmacol; 2016 Jan; 77(1):27-33. PubMed ID: 26645402
[TBL] [Abstract][Full Text] [Related]
6. Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane.
Attia SM; Al-Anteet AA; Al-Rasheed NM; Alhaider AA; Al-Harbi MM
Cancer Chemother Pharmacol; 2009 Sep; 64(4):837-45. PubMed ID: 19184016
[TBL] [Abstract][Full Text] [Related]
7. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
Arroyo PA; Perez RU; Feijoo MA; Hernandez MA
J Cancer Res Ther; 2010; 6(4):573-4. PubMed ID: 21358106
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
[TBL] [Abstract][Full Text] [Related]
9. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
Galetta F; Franzoni F; Cervetti G; Cecconi N; Carpi A; Petrini M; Santoro G
Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
11. Correction: Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.
Attia SM; Ahmad SF; Ansari MA; Nadeem A; Al-Shabanah OA; Al-Harbi MM; Bakheet SA
PLoS One; 2016; 11(10):e0165854. PubMed ID: 27788265
[TBL] [Abstract][Full Text] [Related]
12. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
Spallarossa P; Altieri P; Pronzato P; Aloi C; Ghigliotti G; Barsotti A; Brunelli C
J Pharmacol Exp Ther; 2010 Jan; 332(1):87-96. PubMed ID: 19841470
[TBL] [Abstract][Full Text] [Related]
13. Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Aigner B; Bauernhofer T; Petru E; Niederkorn A; Arzberger EJ; Richtig E
Dermatology; 2014; 229(4):288-92. PubMed ID: 25472626
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Galetta F; Franzoni F; Cervetti G; Regoli F; Fallahi P; Tocchini L; Carpi A; Antonelli A; Petrini M; Santoro G
Biomed Pharmacother; 2010 Apr; 64(4):259-63. PubMed ID: 19932589
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary.
Salih SM; Ringelstetter AK; Elsarrag MZ; Abbott DH; Roti EC
Biol Reprod; 2015 Mar; 92(3):73. PubMed ID: 25609833
[TBL] [Abstract][Full Text] [Related]
16. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
Langer SW; Thougaard AV; Sehested M; Jensen PB
Cancer Chemother Pharmacol; 2012 Feb; 69(2):573-6. PubMed ID: 22143379
[TBL] [Abstract][Full Text] [Related]
17. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
18. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Plandé J; Platel D; Tariosse L; Robert J
Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
[TBL] [Abstract][Full Text] [Related]
19. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane use in the prevention of anthracycline extravasation injury.
Hasinoff BB
Future Oncol; 2006 Feb; 2(1):15-20. PubMed ID: 16556068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
